295 related articles for article (PubMed ID: 25166271)
1. Comparison of visual prognoses between natural course of simple hemorrhage and choroidal neovascularization treated with intravitreal bevacizumab in highly myopic eyes: a 1-year follow-up.
Goto S; Sayanagi K; Ikuno Y; Jo Y; Gomi F; Nishida K
Retina; 2015 Mar; 35(3):429-34. PubMed ID: 25166271
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
Ikuno Y; Sayanagi K; Soga K; Sawa M; Tsujikawa M; Gomi F; Tano Y
Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
[TBL] [Abstract][Full Text] [Related]
3. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization.
Yodoi Y; Tsujikawa A; Nakanishi H; Otani A; Tamura H; Ojima Y; Hayashi H; Yoshimura N
Am J Ophthalmol; 2009 May; 147(5):816-24, 824.e1. PubMed ID: 19211092
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
[TBL] [Abstract][Full Text] [Related]
6. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A
Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia.
Wakabayashi T; Ikuno Y; Gomi F; Hamasaki T; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):591-596.e1. PubMed ID: 19589497
[TBL] [Abstract][Full Text] [Related]
8. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
Sabry D; Gad MA; Enam KM
Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
[TBL] [Abstract][Full Text] [Related]
9. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
11. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
[TBL] [Abstract][Full Text] [Related]
12. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
Mimoun G; Caillaux V; Querques G; Rothschild PR; Puche N; Souied EH
Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
[TBL] [Abstract][Full Text] [Related]
13. Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum.
Finger RP; Charbel Issa P; Schmitz-Valckenberg S; Holz FG; Scholl HN
Retina; 2011; 31(7):1268-78. PubMed ID: 21386758
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
15. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
Wakabayashi T; Ikuno Y; Gomi F
Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
Lalloum F; Souied EH; Bastuji-Garin S; Puche N; Querques G; Glacet-Bernard A; Coscas G; Soubrane G; Leveziel N
Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
[TBL] [Abstract][Full Text] [Related]
17. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization.
Kung YH; Wu TT; Huang YH
Acta Ophthalmol; 2014 Dec; 92(8):e615-20. PubMed ID: 24924911
[TBL] [Abstract][Full Text] [Related]
18. Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy.
Sakai T; Ohkuma Y; Kohno H; Hayashi T; Watanabe A; Tsuneoka H
Br J Ophthalmol; 2014 Dec; 98(12):1642-8. PubMed ID: 25053762
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results.
Peiretti E; Vinci M; Fossarello M
Can J Ophthalmol; 2012 Feb; 47(1):28-33. PubMed ID: 22333848
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
